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Abstract
Introduction: The retinoprotective effect of the 11-amino acid fragment of darbepoetin PRK-002 on the models of 
hypertensive retinal angiopathy and hypertensive neuroretinopathy in Wistar rats was investigated in comparison with 
carbamylated darbepoetin and sulodexide.
Materials and methods: The protective effects of the pharmacological agents were assessed using the following cri-
teria: a semi-quantitative assessment of changes in the eye fundus when performing ophthalmoscopy, the retinal blood 
flow, the b/a coefficient, eNOs expression in retinal vessels, specific number of neuronal nuclei in the inner nuclear 
layer, and p53 expression in the retina.
Results and discussion: A pronounced protective effect, exceeding sulodexide at a dose of 150 LRU/kg and carba-
mylated darbepoetin at a dose of 300 μg/kg when correcting retinal angiopathy was observed in PRK-002 at a dose 
of 4 µg/kg, which expressed in adjustment of the retinal vessels’ calibers, removing retinal arterio-venous crossings, 
reaching the target levels of the retinal microcirculation, the b/a coefficient, and the restoration of eNOs expression in 
the endothelium of retinal vessels. PRK-002 at a dose of 4 µg/kg has a pronounced neuroprotective effect comparable 
to carbamylated darbepoetin at a dose of 300 µg/kg in correction of hypertensive neuroretinopathy, which expressed in 
the normalization of the fundus image, reaching the b/a target values, the specific number of neuronal nuclei in the inner 
nuclear layer, inhibition of p53 expression in the neurons of the inner nuclear and ganglionic layers.
Conclusion: The study revealed angio- and neuroprotective activity of the 11-amino acid fragment of darbepoetin 
PRK-002 in correction of retinal injury formed on the background of hypertension.
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Introduction
Hypertensive retinopathy occurs on average in 66% of 
patients with hypertensive disease (HD) late stages. Age, 
duration of HD, and systolic blood pressure (SBP) values 
have a significant impact on the formation of retinopathy 
and neuroretinopathy (Erden and Bicakci 2012).
The pathogenesis of hypertensive retinopathy is not well 
understood. As for today, there are three main factors in the 
development of hypertensive retinopathy: spasm of the reti-
nal arteries, increased permeability of blood vessels and ath-
erosclerosis. Among the factors of retinal angiopathy forma-
tion, there are hemodynamic disorders and local endothelial 
dysfunction of retinal vessels (Ivanova and Yarosheva 2008, 
Karaca et al. 2014). In case of endothelial dysfunction (ED), 
deformation of the vascular wall and stenosis of the arteri-
oles, a complex nature of hemodynamics is formed, with 
areas with high and low values of shear stresses. An im-
balance between intravascular (reduced perfusion pressure) 
and intraocular pressure is important for the development of 
ischemic neuropathy (Hayreh 2013). A number of studies 
have investigated the possibility of pharmacological correc-
tion of ED in the retina (Karaca et al. 2014, Lu et al. 2015).
In patients with pathological retinal changes on the 
background of arterial hypertension (AH), vascular and 
further neuronal changes are noted, in the pathogenesis 
of which the ED of retinal vessels plays an important 
role. Against the background of arteriospasm and arterio-
sclerosis, retinal ischemia is formed, which is primarily 
evident through pathological changes in the neurons of 
the retinal layers characteristic of ischemic neuropathies 
(Peresypkina et al. 2018).
Hypertensive retinopathy is fraught with complica-
tions, including retinal artery occlusion, optic nerve atro-
phy, and retinal vein thrombosis (Kawasaki et al. 2013). 
Changes in retinal arterioles in HD mirror changes in brain 
arterioles (Hanff et al. 2014). Currently, the primary ther-
apy of patients with hypertensive retinopathy is aimed at 
the normalization of blood pressure (BP) values, and the 
correction of the already established ischemic neuropathy.
In the treatment of retinal vein occlusions in a complex 
drug therapy, endothelial protector sulodexide is used 
(Avetisov et al. 2018). Sulodexide has antithrombotic and 
profibrinolytic effects. The drug is widely used to prevent 
cardiovascular complications in patients with diabetes 
mellitus (DM) (Lauver and Lucchesi 2006). Due to the 
introduction of sulodexide to the laboratory animals with 
experimental diabetes, correction of ED of blood vessels 
is observed (Tyurenkov et al. 2011).
In previous studies, it was shown that carbamylated 
darbepoetin at a dose of 300 µg/kg in rats increased the 
eNOs expression in the endothelium of retinal vessels in 
the correction of experimental hypertensive neuroretinop-
athy. In addition, inhibition of apoptosis in retinal neurons 
was revealed, which was confirmed by a decrease in p53 
protein expression (Peresypkina 2018).
In our opinion, a promising retinoprotector with en-
dothelio- and neuroprotective activity can be an 11-ami-
no acid fragment of darbepoetin, which has a low mo-
lecular weight compared to darbepoetin. In connection 
with the above, it was important to study the possibili-
ties of pharmacological correction of morphofunctional 
retinal injuries using an 11-amino acid fragment of dar-
bepoetin on models of retinal angiopathy and hyperten-
sive neuroretinopathy.
Objective: to improve the efficacy of pharmacolog-
ical correction of morphofunctional retinal injuries us-
ing an 11-amino acid fragment of darbepoetin on mod-
els of hypertensive retinal angiopathy and hypertensive 
neuroretinopathy.
Materials and methods
The experiments were performed in Wistar rats, males 
weighing 250±25 g without any external signs of the di-
sease, which had passed quarantine. During the experi-
ment, the rats were kept in a standard experimental biolo-
gically clean room; the air temperature was 22–24 °C; the 
lighting was 12 h/12 h light/dark cycle, and all the animals 
received granular feed and filtered water. Operations and 
other manipulations on rats were carried out under gene-
ral anesthesia by intraperitoneal (i/p) administration of 
an aqueous solution of chloral hydrate. The animals were 
sacrificed in accordance with The European Convention 
for the Protection of Vertebrate Animals Used for Expe-
rimental and Other Scientific Purposes adopted by the 
Council of Europe (Strasbourg, France, 1986) and Coun-
cil Directive 86/609/EEC of 24.11.1986 on the approxi-
mation of laws, regulations and administrative provisions 
of the Member States regarding the protection of animals 
used for experimental and other scientific purposes by an 
overdose of chloral hydrate administered i/p. The animals 
were divided into groups by stratified randomization with 
stratification by body weight, maintenance and feeding 
conditions, age, as well as operations and manipulations.
Hypertensive retinal angiopathy and hypertensive 
neuroretinopathy simulation
In the study, a model of hypertensive retinal angiopathy was 
used in male Wistar rats, in which N-nitro-L-arginine met-
hyl ether (L-NAME) is administered daily at a dose of 12.5 
mg/kg of rat weight for 28 days. In the pathogenesis of reti-
nal angiopathy in rats, the key point is the formation of ED 
in the retinal vessels, the reduction of NO synthesis and the 
development of AH on the background of vasoconstriction.
Also, a model of hypertensive neuroretinopathy was 
used on male Wistar rats in the experiment, which was 
carried out by raising the intraocular pressure (IOP) for 
5 minutes on the 26th day of the experiment, on the back-
ground of daily administration of L-NAME at a dose of 
12.5 mg/kg for 28 days. One of the links in the patho-
genesis of neuroretinopathy in rats is the development of 
hypertension against the background of NO deficiency, as 
well as ED of retinal vessels. Another link in the patho-
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genesis is the creation of an ischemic episode in the retina 
with increased IOP (Peresypkina et al. 2017).
To measure BP in rats, a non-invasive blood pressure 
measurement system NIBP200 was used in small animals 
on the tail as part of the BIOPAC SYSTEMS MP-150 
complex. The results of the integrated semi-quantitative 
assessment of the fundus state, measurement of retinal 
blood flow, calculation of the b/a coefficient, immunohis-
tochemical study of eNOs expression in the retinal layers 
served as confirmation of the formation of hypertensive 
retinal angiopathy in the experimental animals on the 29th 
day of the experiment.
Confirmation of the formation of hypertensive neu-
roretinopathy in rats on the 29th of the experiment were 
the results of semi-quantitative assessment of changes 
in the eye fundus, measurements of retinal blood flow, 
calculation of the b/a coefficient, the specific number of 
nuclei of neurons of the inner nuclear layer, and an im-
munohistochemical study of eNOs and p53 expression in 
the retinal layers.
Semi-quantitative assessment of changes in the eye 
fundus
To study the fundus of eye in the laboratory rats, opht-
halmoscopy was used on the 29th day of the experiment, 
using an ophthalmoscope Bx a NEITZ, Japan. Eye drops 
with phenylephrine (Irifrin 2.5%, PROMED EXPORTS, 
India) were used for mydriasis by instillation into the con-
junctival sac.
For adults, a single instillation of 2.5% solution is used 
during ophthalmoscopy. To create mydriasis, it is enough 
to inject 1 drop of 2.5% Irifrin into the conjunctival sac. 
One drop of eye drops Irifrin 2.5% contains 0.05 ml of 
the active substance. The conversion factor for an adult 
weighing 70 kg is 39. For rats weighing 250 g, the con-
version factor is 7.0. The calculated dose of Irifrin was 
0.004 ml/kg. A solution of eye drops was administered 
into the conjunctival sac using a micropipette, as per the 
body weight of the rats.
After complete pupil dilation, the ophthalmoscope was 
brought closer to the rat’s eye at a distance of 0.5–2 cm to 
obtain a clear image of the retina. To increase the possi-
bility of obtaining photographs of the fundus, a OI-78M 
lens was applied (VOLK Optical Inc, Mentor, OH, USA).
For further statistical processing, the degree of changes 
in the fundus during ophthalmoscopy against the back-
ground of simulating and correcting retinal angiopathy 
and hypertensive neuroretinopathy was evaluated in 
points (Table 1).
Evaluation of retinal blood flow using laser Doppler 
flowmetry
Retinal blood flow in rats was measured by laser Dop-
pler flowmetry (LDF) on the 29th day of the experiment 
(Peresypkina et al. 2017). Registration was performed 
using a hardware-software complex BIOPAC SYSTEMS 
MP-150,a needle-type sensor TSD-144 (USA), and ACQ-
KNOWLEDGE 4.2. software.
Assessment of the functional state of the retina using 
electroretinography (ERG)
ERG was performed immediately after recording the mi-
crocirculation level. The animals were kept in the dark for 
30 minutes (Zahng et al. 2013), then anesthetized (chloral 
hydrate, 300 mg/kg, i/p) and fixed on a table isolated from 
electromagnetic radiation. The corneal silver electrode 
was placed on the cornea; the reference EL452 needle 
electrode was placed subcutaneously in the cranial region, 
and a ground needle electrode EL450 was placed subcuta-
neously at the base of the tail. A white-light stroboscope 
was connected to an STM200 stimulator (BIOPAC SYS-
TEM Inc., USA) placed behind the animal; registration 
of ERG was carried out in response to a single stimulati-
Table 1. Method of Semi-quantitative Assessment of Changes in the Eye Fundus When Modeling and Correcting Retinal Angiopa-
thy and Hypertensive Neuroretinopathy, points.
Features of eye fundus changes Score
Norm. The optic disc (OD) is round or oval, of pink colour against the background of the fundus. The boundaries of 
OD are clear. OD is located in the plane of the retina. The central retinal vessels emerge at the center of OD. The retinal 
vessels have no anastomoses. The veins and arteries are rectilinear, with no tortuosity; their caliber is uniform. The 
overall background is pink.
0
Angiopathy. Salus-Gunn I symptom. In the eye fundus, there is ”the crossing phenomenon”, which appears due to the 
indentation of the artery at the crossing site with the dilated vein. The vein is dilated on both sides of the crossing. Guist 
symptom – dilation and corkscrew tortuosity of the venules, located around the macula.
1
Angiosclerosis. Copper wire arteries. Salus-Gunn II symptom – swellings at the crossing site of the artery and the 
dilated vein. 2
Salus-Gunn III symptom – the disappearance of the vein at the crossing site due to its forming an arcuate curve, diving 
deep into the retina. Silver wire symptom. Increased vascular permeability. 3
Retinopathy. Soft exudates. Hemorrhages. In the macular zone, there may be deposits of solid star-shaped exudate. 4
Hypertensive neuroretinopathy. Obvious OD discoloration. Swollen OD and peripapillary retina. Hemorrhages and 
foci of soft and solid exudates, indicating increasing ischemia. 5
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on. Evoked potentials were transmitted at a frequency of 
1–1000 Hz, amplified, averaged and presented graphical-
ly on the screen using the BIOPAC-SYSTEMS MP-150 
with ACQKNOWLEDGE 4.2. software (USA). ERG was 
recorded for 0.5 s in each rat in the groups. The ratio of 
amplitudes of b and a ERG waves to the b/a coefficient 
(Shabelnikova et al. 2016) was estimated to assess a de-
gree of functional retinal damage. Out of the ten values 
obtained in each group, the mean was calculated to be 
entered into the protocol.
Assessment of retinal changes using morphometric 
and immunohistochemical studies
The eyes were completely removed along with the ad-
jacent structures on the 29th day of the experiment for 
morphometric examination and were fixed by immersion 
in 10% formalin solution. After fixing, the eyes were sec-
tioned into two parts through the centre and both halves 
were processed into paraffin by routine methods. Also, 
serial sections with a thickness of 5–7 μm were made al-
ong the meridian and stained with haematoxylin and eo-
sin. The stages of histological processing were performed 
using LEICA equipment (Germany).
For microscopy, morphometry and archiving, the pre-
pared microslides were scanned using MIRAX DESK, a 
computerised archiving and image analysis system. The 
image analysis and morphometry were carried out by 
PANNORAMIC VIEWER 1.15.4 software. The quantita-
tive data were recorded in MS Excel spreadsheets.
Counting the specific number of neuronal nuclei in the 
inner nuclear layer was carried out by Avtandilov ‘s grid 
on standard computer images obtained by the system for 
scanning and archiving images MIRAX DESK and PAN-
NORAMIC VIEWER 1.15.4 software. A computer ver-
sion of the 0.3 mm2 grid projected on the image was used.
An immunohistochemical (IHC) study was performed 
according to standard protocols with consideration of 
recommendations of the antibodies manufacturers. Af-
ter standard deparaffinization of the sections mounted on 
adhesive glass slides, a high-temperature unmasking of 
antigens in the citrate buffer was performed. To identi-
fy the reaction, polymer detection systems ULTRA VI-
SION (THERMOSCIENTIFIC, UK) and HISTOFINE 
(NICHIREI BIOSCIENCES, Japan) were used with a 
chromogen – diaminobenzidine.
Research design. Mode of administration and dose of 
pharmacological agents
The study design is presented in Table 2.
In order to correct the hypertensive retinal angiopathy, 
an 11-amino acid fragment of darbepoetin with laborato-
ry code PRK-002 (PHARMAPARK LLC, Russia) in the 
form of lyophilized powder was dissolved in 0.5 ml of 
water for injection to prepare a solution with a concen-
tration of 50 µg/ml, which was injected subcutaneously 
(s/c) behind the shoulder at a dose of 4 µg/kg of rat weight 
(recommendations of PHARMAPARK LLC) once every 
3 days, starting from the first day of the experiment, 30 
min before introduction of L-NAME.
The reference drug carbamylated darbepoetin in the 
form of an injection solution (PHARMAPARK LLC, 
Russia), containing 100 µg of recombinant carbamylated 
darbepoetin alpha in 1 ml of a solution , was administered 
s/c at a dose of 300 µg/kg (recommendations of PHAR-
MAPARK LLC) once every 3 days, starting from the first 
day of the experiment, 30 minutes before the introduction 
of L-NAME in the correction of experimental retinal an-
giopathy (Peresypkina 2018).
Sulodexide in the form of capsules, 250 LRU (Vessel 
Due F, ALFA WASSERMANN S.p.A., Italy) was admin-
istered per os for 28 days at a dose of 150 LRU/kg daily 
(Tyurenkov et al. 2011) in order to correct the experimen-
tal hypertensive retinal angiopathy as a comparison drug.
When studying the possibility of correcting hyperten-
sive neuroretinopathy in Wistar rats, the above pharma-
cological agents were used at similar doses and modes 
of administration. The doses and modes of administration 
of the studied pharmacological agents are based on their 
efficacy in experimental studies (Tyurenkov et al. 2012).
The efficacy of the studied agents on the models of ret-
inal angiopathy and hypertensive neuroretinopathy was 
evaluated on the 29th day of the experiment using ophthal-
moscopy, semi-quantitative assessment of changes in the 
eye fundus, LDF, ERG, morphometric and immunohisto-
chemical studies.
Statistical data processing
For all data, descriptive statistics were used, and the data 
were checked for normal distribution. The distribution 
type was determined by using the Shapiro-Wilk criterion. 
In case of normal distribution, the mean (M) and stan-
dard error of the mean (m) were calculated. The outliers 
at each time point were identified using Grubbs’ statistical 
test. If for some value, the Z was greater than the critical 
value for a given number of measurements (N), this ex-
periment was excluded from further calculations. In cases 
of abnormal distribution, the median (Me) and the quar-
Table 2. The Research Design of the Protective Effects of an 
11-amino Acid Fragment of Darbepoetin PRK-002, Carbamy-
lated Darbepoetin and Sulodexide on the Models of Hyperten-
sive Retinal Angiopathy and Hypertensive Neuroretinopathy.
Wistar rats, males (n=90)
1. Control group, with i/p infusion of 0.9% NaCl solution in 
the equivalent volume for 28 days (n=10)
2. Simulated hypertensive 
retinal angiopathy (n=10)
2. Simulated hypertensive 
neuroretinopathy, (n=10)
3. Correction by PRK-002, 4 
µg/kg (n=10)
3. Correction by PRK-002, 4 
µg/kg (n=10)
4. Correction by carbamylated 
darbepoetin, 300 µg/kg (n=10)
4. Correction by carbamylated 
darbepoetin, 300 µg/kg (n=10)
5. Correction by sulodexide, 
150 LRU/kg (n=10)
5. Correction by sulodexide, 
150 LRU/kg (n=10)
Note: LRU – lipoprotein lipase releasing units.
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tile range (QR) were calculated. Between-group differen-
ces were analyzed by parametric (t-Student criterion) or 
non-parametric (Mann-Whitney test) methods, depending 
on the type of distribution. Differences were determined 
at a 0.05 significance level. The statistical analyses were 
performed using STATISTICA 10.0 software.
Results and discussion
Evaluation of the efficacy of PRK-002, carbamoiliro-
vaniem darbepoetin and sulodexide in the correction 
of experimental hypertensive angiopathy of the retina
This study included 50 Wistar male rats, weighing 225–275 
g. A model of hypertensive retinal angiopathy was used, the 
pathogenesis of which was associated with the development 
of hypertension in rats on the background of daily i/p admi-
nistration of L-NAME at a dose of 12.5 mg/kg for 28 days.
In the control group, SBP was 129.5±9.1 mm Hg, and 
DBP was 92.3±7.2 mm Hg. In the group with adminis-
tration of L-NAME, when simulating retinal angiopathy, 
SBP was 203.6±12.1 mm Hg. (p<0.05 in comparison 
with the control group), and DBP was 162.5±9.8 mm Hg 
(p<0.05 in comparison with the control group). The re-
sults of blood pressure measurements in groups with the 
introduction of the studied pharmacological agents and 
reference drugs are presented in Table 3.
Against the background of injecting PRK-002 at a dose 
of 4 µg/kg, a moderate decrease was observed in SBP – 
by 22.3% (p<0.05 in comparison with the group with the 
pathology simulation) and in DBP – by 29.1% (p<0.05 
in comparison with the group with the pathology simula-
tion). It should be noted that the values of SBP and DBP in 
the group with the introduction of PRK-002 do not reach 
the target values. The moderate hypotensive effect of 
PRK-002 is likely to be associated with an increased eNOs 
activity and increased NO synthesis. In the groups with 
the introduction of carbamylated darbepoetin at a dose of 
300 µg/kg, as well as sulodexide at a dose of 150 LRU/
kg, there was no significant decrease in SBP and DBP in 
comparison with the group with the pathology simulation. 
In the group with the introduction of carbamylated dar-
bepoetin, there was a slight decrease in SBP and DBP in 
comparison with the group with the pathology simulation.
On the 29th day of the experiment, the rats in all groups 
were anesthetized to perform ophthalmoscopy. An exam-
ple of an image of the eye fundus of a Wistar rat of the 
control group is shown in Figure 1A and has the follow-
ing description: OD is round or oval; the color of OD is 
pale pink; its boundaries are clear. OD lies in the plane of 
Table 3. Influence of PRK-002, Carbamylated Darbepoetin and 
Sulodexide on Systolic and Diastolic Blood Pressure in Rats on 
29th Day of the Experiment in Correction of Hypertensive Reti-
nal Angiopathy (M±m; n=10), mm Hg.
Experimental groups SBP (mm Hg)
DBP 
(mm Hg)
1. Control 129.5±9.1 92.3±7.2
2. Simulated hypertensive retinal 
angiopathy
203.6±12.1* 162.5±9.8*
3. Correction by PRK-002, 4 µg/kg 158.1±11.5*у 115.2±8.2*у
4. Correction by carbamylated 
darbepoetin, 300 µg/kg
190.3±11.6* 150.7±8.9*
5. Correction by sulodexide, 150 
LRU/kg
200.5±10.4* 152.0±7.9*
Note: SBP – systolic blood pressure, DBP – diastolic blood 
pressure. * – p<0.05 in comparison to the control group; у – 
p<0.05 in comparison to the group with pathology simulation.
A B
Figure 1. Eye fundus images of Wistar rats: A – from the control group; B – with the simulated hypertensive retinal angiopathy. 
Note: SW – silver wire symptom.
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A
B C
Figure 2. Eye fundus image of rats with correction of hypertensive retinal angiopathy by: A – PRK-002 at a dose of 4 µg/kg, 
B – carbamylated darbepoetin at a dose of 300 µg/kg , C – sulodexide at a dose of 150 LRU/kg.
the retina; the retina adheres firmly to the choroid. Retinal 
vessels are rectilinear; the caliber is uniform, and there is 
no tortuosity. The general background of the retina is pink.
An example of the image of the eye fundus of a Wistar 
rat in the simulation of retinal angiopathy is shown in Fig-
ure 1B and has the following description: OD is round or 
oval and stands out against the general background of the 
retina with its pink colour. Its boundaries are clear. Veins 
are dilated. Arteries are narrowed (filamentous). There are 
arterio-venous crosses and the silver wire symptom.
The ophthalmoscopic image in the correction of retinal 
angiopathy by PRK-002 at a dose of 4 µg/kg is shown in 
Figure 2A and has a description close to the norm: OD is 
round or oval and stands out against the fundus with its 
pale pink colour. OD has clear boundaries and lies in the 
plane of the retina. Retinal vessels are rectilinear, there 
is no tortuosity of veins. The general background of the 
retina is pink.
The observed protective effect in the eye fundus of 
Wistar rats with the injection of PRK-002 may be asso-
ciated with eNOs activation and increased NO synthesis 
in blood vessels of the retina, which eventually leads to 
vasodilation of the retinal arteries.
When carbamylated darbepoetin at a dose of 300 µg/kg 
is administered to rats for the correction of retinal angiop-
athy, there is venous plethora, arterial spasm, and vascular 
tortuosity (Fig. 2B).
When injecting sulodexide at a dose of 150 LRU/kg, 
the eye fundus image is close to normal; there is still a 
slight spasm of the retinal arteries, but no arteriovenous 
crosses were noted (Fig. 2C). The protective effect of su-
lodexide on the fundus in the correction of L-NAME-in-
duced retinal angiopathy is likely to be associated with 
endothelium-dependent vasodilation of retinal vessels.
The results of a semi-quantitative assessment of the 
fundus state in the experimental groups are presented in 
Table 4.
Based on the data of the semi-quantitative assessment 
of changes in the eye fundus on the model of hypertensive 
retinal angiopathy, it follows that the studied drugs have a 
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protective effect in the descending order: PRK-002, 4 µg/
kg > sulodexide, 150 LRU/kg > carbamylated darbepoe-
tin, 300 µg/kg.
In the group with the simulated retinal angiopathy, the 
level of retinal blood flow decreased by 41.9% (p<0.05) 
compared to the mean value in the control group. When 
correcting the pathology by means of PRK-002 at a dose 
of 4 µg/kg, the blood flow level increased by 68.6% 
(p<0.05) compared to the group without correction and 
did not differ significantly from the mean value of the 
control group. The correction of the pathology by car-
bamylated darbepoetin at a dose of 300 µg/kg, the level 
of the microcirculation increased by 24.1% (p<0.05) in 
comparison with the group without correction, but did not 
reach the target values. When correcting with sulodexide 
at a dose of 150 LRU/kg, the level of microcirculation 
increased by 63.1% (p<0.05) compared to the mean value 
in the group without correction of the pathology.
Based on the assessment data of the microcirculation 
level in the retina in the experimental groups, it follows 
that the studied drugs positively influence the condition 
of retinal blood flow in the descending order: PRK-002, 
4 µg/kg > sulodexide, 150 LRU/kg > carbamylated dar-
bepoetin, 300 µg/kg. Presumably, the activation of eNOs 
in retinal vessels in the correction of hypertensive retinal 
angiopathy by means of the investigated pharmacological 
agents leads to endothelium-dependent vasodilation, re-
sulting in marked positive dynamics of microcirculation 
in the retina.
In each group, the b/a coefficient was calculated, the 
values of which are presented in Table 5.
Thus, based on the obtained values of the b/a coeffi-
cient in the experimental groups, it follows that the stud-
ied drugs have a positive effect on the electrophysiolog-
ical state of the retina in the correction of hypertensive 
retinal angiopathy in descending order: PRK-002, 4 µg/
kg > sulodexide, 150 LRU/kg) > carbamylated darbepoi-
etin, 300 µg/kg.
IHC studies revealed a marked decrease in the еNOs 
expression in the blood vessels of the retina in the simulat-
ed hypertensive retinal angiopathy in comparison with the 
images in the control group. In the control group, еNOs 
expression was observed at the level of the ganglionic 
layer, namely in the endothelium of the retinal vessels, 
as well as in the capillaries at the level of the outer retinal 
layer. In the experimental groups, on the background of 
correction of retinal angiopathy by means of PRK-002 at 
a dose of 4 µg/kg; carbamylated darbepoetin at a dose 
of 300 µg/kg; and sulodexide at a dose of 150 LRU/kg, 
еNOs expression was restored in the vascular endothe-
lium at the level of the ganglionic layer, the outer retinal 
layer (Fig. 3).
Thus, the result of IHC revealed that the correction of 
the hypertensive retinal angiopathy by PRK-002 at a dose 
of 4 µg/kg; by carbamylated darbepoetin at a dose of 300 
µg/kg; or by sulodexide at a dose of 150 LRU/kg restored 
the eNOs expression in the endothelium of the retinal ves-
sels and capillaries of the outer retinal layer, indicating 
recovery of endothelial function in the retinal vessels.
The results of a complex analysis, including an integral 
semi-quantitative assessment of the eye fundus during 
ophthalmoscopy, measurement of retinal microcircula-
tion, quantitative assessment of the functional state of the 
retina, the results of IHC studies on the 29th day of the 
experiment, revealed that the most pronounced protective 
effect, superior to that of the reference drugs sulodexide 
at a dose of 150 LRU/kg and carbamylated darbepoethin 
at a dose of 300 µg/kg in the correction of experimental 
retinal angiopathy, is characteristic of an 11-amino acid 
fragment of darbepoetin PRK-002 at a dose of 4 µg/kg, 
which is reflected in the adjustment of the retinal vessels 
calibers, elimination of arterio-venous crosses in the ret-
ina, reaching the target values of the level of microcircu-
lation in the retina, and the b/a coefficient, restoration of 
eNOs expression in the vascular endothelium at the level 
of the ganglionic layer and the outer retinal layer.
Evaluation of the efficacy of PRK-002, carbamylated 
darbepoetin and sulodexide in the correction of expe-
rimental hypertensive neuroretinopathy
This study included 50 Wistar male rats, weighing 225–
275 g. In the control group, SBP was 129.5±9.1 mm Hg 
and DBP was 92.3±7.2 mm Hg. In the group with the 
injection of L-NAME when simulating hypertensive 
neuroretinopathy, SBP was 198.5±14.3 mm Hg (p<0.05 
in comparison with the control group) and DBP was 
156.1±10.3 mm Hg.art. (p<0.05 in comparison with the 
control group). Against the background of the injection 
of PRK-002 at a dose of 4 µg/kg, there was a moderate 
Table 4. Influence of PRK-002, Carbamylated Darbepoetin and 
Sulodexide on the Results of Semi-quantitative Assessment of 
Changes in the Eye Fundus in Correction of Hypertensive Reti-
nal Angiopathy (М±m; n=10), points.
Experimental groups Score
1. Control 0.2±0.1
2. Simulated hypertensive retinal angiopathy 3.2±0.1*
3. Correction by PRK-002, 4 µg/kg 0.3±0.2у
4. Correction by carbamylated darbepoetin, 300 µg/kg 0.8±0.2у
5. Correction by sulodexide, 150 LRU/kg 0.5±0.2у 
Note: * – p 0.05 in comparison to the control group; у – p<0.05 
in comparison to the group with pathology simulation.
Table 5. Influence of PRK-002, Carbamylated Darbepoetin and 
Sulodexide on the b/a Coefficient When Correcting Hyperten-
sive Retinal Angiopathy (М±m; n=10), R.U.
Experimental groups b/a
1. Control 2.60±0.07
2. Simulated hypertensive retinal angiopathy 2.20±0.13*
3. Correction by PRK-002, 4 µg/kg 2.50±0.12у 
4. Correction by carbamylated darbepoetin, 300 µg/kg 2.40±0.07 
5. Correction by sulodexide, 150 LRU/kg 2.50±0.10у 
Note: * – p<0.05 in comparison to the control group; у – p<0.05 
in comparison to the group with pathology simulation.
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Figure 3. Examples of eNOs expression in the retina of rats: A – from control group, B – with retinal angiopathy simulation, C – 
with the correction of retinal angiopathy by PRK-002 at a dose of 4 µg/kg, D – with the correction by carbamylated darbepoetin at 
a dose of 300 µg/kg, E – with the correction by sulodexide at a dose of 150 LRU/kg. Immunohistochemical reaction. Microphoto. 
x100. Note: the arrows indicate the vessels with a pronounced eNOs expression.
B
C
DE
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decrease in SBP by 22.4%, p<0.05 and DBP – by 26.9%, 
p<0.05 in comparison with the group with the model of 
pathology. The values of SBP and DBP in the group with 
the injection of PRK-002 did not reach the target values. 
In the groups with the injection of carbamylated darbe-
poetin at a dose of 300 µg/kg and sulodexide at a dose of 
150 LRU/kg, there was no significant decrease in BP in 
comparison with the group with the model of pathology. 
In the group with the injection of carbamylated darbepoe-
tin, there was a slight decrease in BP in comparison with 
the group with the model of pathology.
Research Results in Pharmacology 5(3): 43–55 51
A
B C
D E
Figure 4. The image of the eye fundus of the rat: A, B – with hypertensive neuroretinopathy model, C – with the injection of 
PRK-002 at a dose of 4 µg/kg, D – with the injection of carbamylated darbepoetin at a dose of 300 µg/kg, E – with the injection of 
sulodexide at a dose of 150 LRU/kg. Note: H – hemorrhage, SE – soft exudate, SW – of silver wire symptom.
The eye fundus image in rats with hypertensive neu-
roretinopathy model is the following: OD is edematous 
and enlarged. The boundaries of OD are not clear. There 
are foci of soft exudate. The veins are full and tortuous in 
the periphery. Gunn’s crossing sign. Silver wire symptom. 
Spot hemorrhages (Fig. 4A). The ophthalmoscopic image 
in the correction of hypertensive neuroretinopathy by 
PRK-002 at a dose of 4 µg/kg is shown in Figure 4B and 
has a description close to the norm. On the background of 
the correction of pathology by carbamylated darbepoetin, 
there is slight venous congestion. The state of OD is close 
to normal. The general background is pink (Fig. 4C). The 
observed protective effect in the eye fundus with the in-
jection of PRK-002 and carbamylated darbepoetin on the 
model of hypertensive neuroretinopathy may be associ-
ated with the activation of eNOs in blood vessels of the 
retina and inhibition of p53 expression in neurons of the 
retina. Against the background of the injection of sulo-
dexide at a dose of 150 LRU/kg, a small spasm of the ret-
inal arteries remains; there are no arterio-venous crosses; 
OD is edematous, and the edema spreads to the retina. 
The retina is pale (Fig. 4G).
The results of the semi-quantitative assessment of 
changes in the eye fundus in the experimental groups are 
presented in Table 6.
Based on the obtained data of the semi-quantitative as-
sessment of changes in the eye fundus on the model of hy-
pertensive neuroretinopathy, it follows that the substances 
have the protective effect in descending order: PRK-002, 
4 µg/kg (carbamylated darbepoetin, 300 µg/kg) > sulo-
dexide, 150 LRU/kg.
The results of the LDF are presented in Table 7.
Based on the obtained data of the assessment the mi-
crocirculation level in the retina in the experimental 
groups on the hypertensive neuroretinopathy model, it 
follows that the substances have a positive effect on the 
state of retinal blood flow in descending order: PRK-002, 
4 µg/kg > sulodexide, 150 LRU/kg > carbamylated dar-
bepoietin, 300 µg/kg.
In each experimental group, the coefficient b/a was cal-
culated, the values of which are presented in Table 8.
Thus, based on the obtained values of the b/a coeffi-
cient in the experimental groups, it follows that the sub-
stances have a positive effect on the electrophysiological 
Table 6. Influence of PRK-002, Carbamylated Darbepoetin and 
Sulodexide on the Results of Semi-quantitative Assessment of 
Changes in theEye Fundus in Correction of Hypertensive Neu-
roretinopathy (М±m; n=10), points.
Experimental groups Score
1. Control 0.2±0.1
2. Simulated hypertensive neuroretinopathy 4.9±0.1*
3. Correction by PRK-002, 4 µg/kg 0.2±0.2у
4. Correction by carbamylated darbepoetin, 300 µg/kg 0.1±0.1у
5. Correction by sulodexide, 150 LRU/kg 4.5±0.3* 
Note: * – p<0.05 in comparison to the control group; у – p<0.05 
in comparison to the group with pathology simulation.
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state of the retina in the correction of hypertensive neu-
roretinopathy in descending order: PRK-002, 4 µg/kg 
(carbamylated darbepoetin, 300 µg/kg) > sulodexide, 150 
LRU/kg.
The results of the counting of the specific number of 
neuronal nuclei in the inner nuclear layer in the experi-
mental groups are presented in Table 9.
A neuroprotective activity in relation to neurons of the 
inner nuclear layer of the retina is expressed almost equal-
ly in PRK-002 at a dose of 4 µg/kg and in carbamylated 
darbepoetin at a dose of 300 µg/kg, significantly exceed-
ing the activity of sulodexide at a dose of 150 LRU/kg on 
the model of hypertensive neuroretinopathy.
The IHC study revealed a pronounced decrease in the 
eNOs expression in the retinal vessels in a hypertensive 
neuroretinopathy simulation in comparison with the im-
ages of the control group. In the experimental groups on 
the background of correction of hypertensive neuroreti-
nopathy by PRK-002 at a dose of 4 µg/kg; carbamylat-
ed darbepoetin at a dose of 300 µg/kg; or sulodexide at 
a dose of 150 LRU/kg, the eNOs expression returned to 
normal in vascular endothelium at the level of the gangli-
onic layer and the outer retinal layer. In the group with 
pathology simulation, there was activation of apoptosis, 
as evidenced by an increase in the expression of p53 pro-
tein in neurons of the retina. On the background of correc-
tion by PRK-002; carbamylated darbepoetin, a decrease 
in the p53 expression was observed, which indicated the 
inhibition of apoptosis in the retina. When correcting the 
pathology by sulodexid, there was no decrease in the p53 
expression in the neurons of the retina.
The results of a complex analysis, including an integral 
semi-quantitative assessment of the eye fundus changes 
during ophthalmoscopy, measurement of retinal microcir-
culation, quantitative assessment of the functional state of 
the retina, the results of counting the specific number of 
nuclei of neurons of the inner nuclear layer, IHC studies 
on the 29th day of the experiment, revealed that the most 
pronounced neuroprotective effect comparable to the refer-
ence drug carbamylated darbepoietin at a dose of 300 µg/
kg in the correction of experimental hypertensive neuroret-
inopathy was observed in PRK-002 at a dose of 4 µg/kg, 
which expressed in reaching the target values of the b/a co-
efficient, the specific number of neuronal nuclei in the in-
ner nuclear layer, and inhibition of p53 protein expression 
in the neurons of the inner nuclear and ganglionic layers.
Against the background of correction of hypertensive 
neuroretinopathy by carbamylated darbepoethine at a 
dose of 300 µg/kg, the level of microcirculation does not 
reach the target values, while the correction by PRK-002 
at a dose of 4 µg/kg restores the blood flow level to the 
values of the control group.
On the background of correction of the pathology by su-
lodexide at a dose of 150 LRU/kg, there happens mainly 
the correction of vascular changes of the retina, without any 
significant effect on the state of the neurons of the retina.
Among the pharmacological strategies for the correc-
tion of retinal injuries, of interest is the use of low molec-
ular weight derivatives of darbepoetin for cytoprotection, 
realized through the activation of heterodimer receptors 
to erythropoietin, and for endothelioprotection of retinal 
vessels (Peresypkina et al. 2018).
The evidence of potential erythropoietin receptors 
that can mediate the protective function of erythropoietin 
with an emphasis on the nervous system is summarized. 
In particular, in addition to EpoR, three other potential 
neuroprotective Epo receptors are discussed: (1) a heter-
oreceptor consisting of EpoR and a common beta receptor 
(βcR), (2) an ephrin receptor (Eph) B4, and (3) a CRLF3 
receptor (Ostrowski and Heinrich 2018). βcR is associat-
ed with EpoR, forming an Epo-sensitive protective het-
Table 7. Influence of PRK-002, Carbamylated Darbepoetin and 
Sulodexide on the Level of Retinal Microcirculation When Cor-
recting Simulated Hypertensive Neuroretinopathy (M±m), per-
fusion units.
Experimental groups
Level of micro-
circulation, P.U.
1. Control 743.0±20.9
2. Simulated hypertensive neuroretinopathy 417.2±13.1*
3. Correction by PRK-002, 4 μg/kg 704.5±21.1у
4. Correction by carbamylated darbepoetin, 
300 μg/kg
592.4±9.6*у
5. Correction by sulodexide, 150 LRU/kg 636.4±19.8*у
Note: P.U. – perfusion units; * p<0.05 compared to the control 
group; у p<0.05 compared to the group with simulated hyperten-
sive neuroretinopathy.
Table 8. Influence of PRK-002, Carbamylated Darbepoetin and 
Sulodexide on the Values of the b/a Coefficient When Correcting 
Simulated Hypertensive Neuroretinopathy (M±m; n=10), R.U.
Experimental groups b/a
1. Control 2.60±0.07
2. Simulated hypertensive neuroretinopathy 1.91±0.08*
3. Correction by PRK-002, 4 μg/kg 2.50±0.13у 
4. Correction by carbamylated darbepoetin, 300 μg/kg 2.51±0.06у
5. Correction by sulodexide, 150 LRU/kg 2.31±0.10*у 
Note: * – p<0.05 in comparison to the control group; у – p<0.05 
in comparison to the group with pathology simulation.
Table 9. Influence of PRK-002, Carbamylated Darbepoetin and 
Sulodexide on the Specific Number of Neuronal Nuclei in the 
Inner Nuclear Layer When Correcting Simulated Hypertensive 
Neuroretinopathy (М±m; n=10), absolute units.
Experimental groups
Number 
of nuclei
1. Control 12.8±0.9
2. Simulated hypertensive neuroretinopathy 8.5±0.7*
3. Correction by PRK-002, 4 μg/kg 12.1±0.9у
4. Correction by carbamylated darbepoetin, 300 μg/kg 11.7±0.8у
5. Correction by sulodexide, 150 LRU/kg 9.2±0.7*
Note: * – p<0.05 in comparison to the control group; у – p<0.05 
in comparison to the group with pathology simulation.
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eroreceptor (Bennis et al. 2012, Cendrowski et al. 2016). 
Selective activation of heterodimeric EpoR/βcR, rather 
than homodimeric EpoR, was demonstrated for carbamy-
lated erythropoietin, peptides originating from or associ-
ated with helix-B Epo (Brines 2010).
There were reports about neuroprotective effects of 
NeuroEPO, a low-sialic form of erythropoietin, on oxi-
dative stress caused by excitotoxicity of glutamate. The 
effect of NeuroEPO on apoptosis caused by excitotoxic-
ity of glutamate in primary cultures of neurons derived 
from the anterior brain of Wistar rat embryos after 17 
days of pregnancy was analyzed. Excitotoxicity was in-
duced after nine days of in vitro cultivation by treatment 
with a culture medium containing 100 µm glutamate for 
15 minutes. Apoptosis was analyzed after 24 hours. It 
was shown that neurons treated with glutamate exhibited 
loss of dendrites that did not come into contact with the 
neighboring cells, and that NeuroEPO was able to main-
tain the morphological characteristics of the control. The 
images of immunocytochemistry show that glutamate 
causes cell death, and this is partially avoided when Neu-
roEPO is added to the culture medium. The activation of 
internal apoptotic pathways was analyzed. The reduced 
Bcl-2/Bax ratio, increased cytochrome C Release, and 
the expression and activity of caspase-3 observed in glu-
tamate-treated cells were restored by NeuroEPO. The 
results of this study show that NeuroEPO protects cor-
tical neurons from glutamate-induced apoptosis by acti-
vating Bcl-2 and inhibits glutamate-induced activation of 
caspase-3 (Garzón et al. 2018).
The results of this study provide a theoretical justifi-
cation for new possibilities of correction of vascular and 
neuronal retinal injuries on the background of AH, aimed 
at: correction of local ED of retinal vessels; correction of 
generalized ED and, as a consequence, a moderate de-
crease in BP; and inhibition of p53 protein expression in 
retinal neurons. The hypothetical mechanism of realiza-
tion of protective effects of an 11-amino acid fragment of 
darbepoetin on models of retinal angiopathy and hyper-
tensive neuroretinopathy is presented in Figure 5.
Conclusion
The results of this study rare the following:
1. A pronounced protective action, superior to that 
of the reference drugs sulodexide at a dose of 150 
LRU/kg and carbamylated darbepoetin at a dose of 
300 µg/kg in the correction of hypertensive retinal 
angiopathy in Wistar rats, is revealed in an 11-ami-
no acid fragment of darbepoetin PRK-002 at a dose 
of 4 µg/kg, which is expressed in the adjustment of 
the caliber of retinal vessels, elimination of arte-
rio-venous crosses in the retina, reaching the target 
values of the microcirculation level in the retina, the 
b/a coefficient, restoration of eNOs expression in 
the vascular endothelium at the level of the gangli-
onic layer and the outer retinal layer.
2. A protective effect on the model of hypertensive 
retinal angiopathy, inferior to that of PRK-002 at a 
dose of 4 µg/kg, is revealed in carbamylated darbe-
poetin at a dose of 300 µg/kg, which is expressed in 
a significant 75% decrease (p<0.05) in scores of the 
semi-quantitative assessment of the fundus state, 
detected in ophthalmoscopy, compared with the 
mean value of the group without correction of the 
pathology; restoration of eNOs expression in the en-
dothelium of retinal vessels at the level of the gan-
glionic layer and the outer retinal layer. The target 
values of the microcirculation level in the retina and 
the b/a coefficient in the group with the injection of 
carbamylated darbepoietin are not reached.
3. A protective effect in the hypertensive retinal angi-
opathy simulation, inferior to that of PRK-002 at a 
dose of 4 µg/kg, is revealed in sulodexide at a dose 
of 150 LRU/kg, resulting in a significant 84% de-
crease (p<0.05) in scores of the semi-quantitative 
assessment of the fundus state revealed by oph-
thalmoscopy in comparison with the mean value of 
the group without the pathology correction; a sig-
Figure 5. Hypothetical mechanism of protective action of PRK-002 at a dose of 4 µg/kg in the hypertensive retinal angiopathy and 
hypertensive neuroretinopathy simulation.
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nificant 63% increase in the microcirculation level 
in the retina (p<0.05) in comparison with the mean 
value in the group without correction; reaching the 
target values of b/a; and the restoration of eNOs ex-
pression in the endothelium of retinal vessels.
4. The results of a complex analysis, including an inte-
gral semi-quantitative assessment of the eye fundus 
state, measuring the level of retinal microcircula-
tion, quantitative assessment of the functional state 
of the retina, the results of morphometric and IHC 
studies, revealed that the most pronounced neuro-
protective effect, comparable to that of carbamylat-
ed darbepoethin at a dose of 300 µg/kg in the cor-
rection of hypertensive neuroretinopathy in Wistar 
rats, is revealed in PRK-002 at a dose of 4 µg/kg, 
which is expressed in the normalization of the eye 
fundus image, reaching the target values of the b/a 
coefficient, specific number of neuronal nuclei in 
the inner nuclear layer, inhibition of p53 protein ex-
pression in neurons of the inner nuclear and gangli-
onic layers. The microcirculation level in the retina 
in the group with the injection of PRK-002 at a dose 
of 4 µg/kg reaches the target values; there is a res-
toration of eNOs expression in the retinal vessels.
5. Against the background of correction of hyperten-
sive neuroretinopathy by carbamylated darbepo-
ethin at a dose of 300 µg/kg, normalization of the 
eye fundus image is observed, but the microcircu-
lation level does not reach the target values; the 
values of the b/a coefficient and the specific num-
ber of neuronal nuclei in the inner nuclear layer in 
the group do not differ significantly from the norm; 
eNOs expression is restored in the endothelium of 
retinal vessels and capillaries of the outer retinal 
layer, which indicates the restoration of the endo-
thelium function of the retina; inhibition of p53 ex-
pression is observed in retinal neurons.
6. On the background of the correction of hyperten-
sive neuroretinopathy by sulodexide at a dose of 
150 LRU/kg, mainly correction of vascular changes 
in the retina is observed, probably due to restoration 
of eNOs expression in the endothelium of retinal 
vessels, without significant effect on the state of the 
neurons of the retina.
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